SIGACHI

What Sigachi Industries promised, and what happened

Every commitment management made on a call, tracked from the quarter it was made — reaffirmed, revised, diluted or quietly dropped.

Guidance record · Q1 FY27

what the last two calls moved 17 tracked 0 delivered 2 missed 15 open
  • Revenue Growth missed said Q4 FY25 Promised: >25% growth over the next 2 to 3 years Q1 FY27: Historical promise that was missed in FY26. Not discussed.
  • EBITDA Margin delayed said Q4 FY25 Promised: beyond 25% Q1 FY27: Management reiterated FY27 guidance of 18%, which is significantly below the original >25% target. Q1 margin was 13.6%. The promise remains significantly delayed.
  • Revenue from Cystic Fibrosis API on track said Q3 FY26 Promised: INR 250 crores after 12 months post-commercialization Q1 FY27: Management stated that revenues from the cystic fibrosis product are expected by next year, indicating the project is progressing.

The rest of the ledger

Above is what the last two calls moved. Pro opens all 17 tracked commitments for Sigachi Industries — every quarter's revision, the source quote behind each one, and the topics management has stopped answering.

See what Pro opens